INFECTIOUS DISEASES IN CLINICAL PRACTICE, published by Lippincott Williams & Wilkins, is a crucial resource in the field of infectious diseases and microbiology. With an ISSN of 1056-9103 and an E-ISSN of 1536-9943, this journal has been a platform for scholarly communication since its inception in 1992, now spanning over two decades of continuous publication. The journal primarily focuses on the latest research developments, case studies, and clinical practices relevant to infectious diseases, making it an indispensable tool for researchers, healthcare professionals, and students alike. Although it is currently categorized in the Q4 quartile for both Infectious Diseases and Medical Microbiology, it continues to strive for excellence and relevance in a rapidly evolving field. By facilitating open access to impactful articles (note: Open Access not applicable), the journal aims to enhance global understanding and management of infectious diseases, ensuring that practitioners are well-equipped to confront contemporary challenges in this critical area of public health. Situated in the United States at TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103, INFECTIOUS DISEASES IN CLINICAL PRACTICE plays an essential role in fostering academic discourse and advancing clinical knowledge.

The Journal of Global Antimicrobial Resistance, published by Elsevier Scientific Ltd, is a premier open access journal dedicated to addressing the critical issue of antimicrobial resistance on a global scale. Established in 2013 and significantly gaining traction as an open access platform since 2020, this journal serves as an essential resource for researchers, healthcare professionals, and policy makers invested in immunology, microbiology, and associated fields. With an impressive impact factor reflected through its consistent ranking in the Q2 category across multiple disciplines, including Microbiology and Immunology – where it ranks #29 out of 140 in Medical Microbiology – the journal ensures high-quality peer-reviewed articles that push the boundaries of current knowledge and practice. By offering a global perspective on research trends and public health implications, the Journal of Global Antimicrobial Resistance plays a pivotal role in advancing the scientific discourse necessary to combat the rising tide of antimicrobial resistance worldwide.

Revista de Epidemiologia e Controle de Infeccao, published by Universidade de Santa Cruz do Sul, stands as a vital resource for scholars and practitioners in the fields of epidemiology and infection control. This open-access journal, available since 2011, fosters the dissemination of high-quality research and practice-based knowledge aimed at enhancing public health and improving infection management strategies. With its commitment to sharing invaluable insights from Brazil and beyond, the journal encourages broader participation in critical discussions surrounding infectious diseases. Although specific metrics such as the HIndex and Scopus rankings are currently omitted, the journal's relevance is underscored by its open accessibility, allowing a global audience of researchers, healthcare professionals, and students to engage with innovative studies and findings in this essential area of public health.

The American Journal of Infection Control is a leading peer-reviewed publication dedicated to advancing the field of infection prevention and control. Published by Mosby-Elsevier, this journal has been a crucial resource since its inception in 1980, focusing on the intersection of infectious diseases, public health, and health policy. As of 2023, it holds an impressive Q1 ranking in both Health Policy and Public Health, Environmental and Occupational Health, while also achieving Q2 rankings in Epidemiology and Infectious Diseases. With an increasing impact factor and a strong reputation reflected in its Scopus rankings, the journal appeals to researchers, health professionals, and students committed to preventing the spread of infections and enhancing healthcare safety. Although it does not currently offer Open Access, the journal ensures broad dissemination of its vital research through various subscription options. By fostering interdisciplinary collaboration and evidence-based practices, the American Journal of Infection Control plays a pivotal role in shaping effective infection control policies and practices worldwide.

Welcome to the Journal of Microbiology Immunology and Infection, a premier academic publication established in 1998 and now proudly owned by Elsevier Taiwan. As an Open Access journal since 2016, it provides unrestricted access to groundbreaking research in the fields of immunology, microbiology, and infectious diseases, making it an essential resource for researchers, practitioners, and students alike. The journal holds impressive rankings, including Q1 status in categories such as Infectious Diseases and Microbiology (medical), and a notable 92nd percentile in its Scopus ranking for Medicine - Infectious Diseases. With a dedicated focus on advancing knowledge and fostering collaboration within the scientific community, the Journal of Microbiology Immunology and Infection is committed to publishing high-impact research that significantly influences practice and policy in healthcare and life sciences. The journal is also recognized for its contribution to the ongoing dialogue surrounding contemporary issues in immunology and infection, positioning it as a vital platform for scholarly exchange and innovation.

Infection and Chemotherapy, an esteemed journal published by the Korean Society of Antimicrobial Therapy, focuses on the dynamic fields of infectious diseases and pharmacology. With an ISSN of 2093-2340 and an E-ISSN of 2092-6448, this peer-reviewed, open-access journal has been providing a crucial platform for research dissemination since 2008. Based in South Korea, it boasts a significant impact in the academic community, as evidenced by its Q2 ranking in both Infectious Diseases and Pharmacology categories for 2023. It holds a Scopus rank of 64 out of 272 in Pharmacology and 98 out of 344 in Infectious Diseases, showcasing its prominence and the quality of research it publishes. With a focus on advancing scientific knowledge, Infection and Chemotherapy is committed to fostering essential dialogues among researchers, clinicians, and students, making it a vital resource for those engaged in the fight against infectious diseases and the development of effective therapeutic protocols.

Journal of the Pediatric Infectious Diseases Society, published by Oxford University Press, stands as a pivotal platform for advancing knowledge in the realm of pediatric infectious diseases. With an ISSN of 2048-7193 and an E-ISSN of 2048-7207, this esteemed journal has garnered significant recognition in the academic community, achieving influential rankings such as Q1 in Pediatrics, Perinatology and Child Health and Q2 in Infectious Diseases. With converged years from 2012 to 2024, it aims to publish cutting-edge research, reviews, and clinical practices that address the challenges and innovations in the field. The journal's strong performance, reflected in its Scopus ranks (33rd percentile in Pediatrics and 97th in Infectious Diseases), underscores its impact on the global healthcare landscape. As a non-open access journal, it provides exclusive content essential for researchers, medical professionals, and students dedicated to enhancing pediatric healthcare outcomes.

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, published by Elsevier Science Inc, is a leading journal in the fields of Infectious Diseases, Microbiology, and Medicine. Since its inception in 1983, this esteemed journal has consistently provided a platform for original research and comprehensive reviews that advance the understanding of diagnostic microbiology and its implications for infectious diseases. With an impressive impact factor placing it in the Q2 category in multiple relevant fields as of 2023, it stands out with Scopus rankings reinforcing its significance in academia, ranking #136 out of 344 in Infectious Diseases and #64 out of 140 in Medical Microbiology. This journal is essential for researchers, healthcare professionals, and students who seek to stay abreast of the latest developments and trends in infectious diagnostics. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE is committed to fostering excellence in research quality and academic rigor, ensuring accessibility to vital knowledge for addressing some of the most pressing health challenges of our time.

BMC Infectious Diseases is a premier open-access journal published by BMC in the United Kingdom, dedicated to the field of infectious diseases. Established in 2001, this journal has been at the forefront of disseminating high-quality, peer-reviewed research, contributing significantly to the global understanding of infectious pathogens and their impact on public health. With a 2023 Scopus ranking of #100 out of 344 in the Medicine - Infectious Diseases category, and a notable Q1 quartile classification, it stands as a vital resource for researchers and professionals alike. Authors benefit from the journal's broad reach and visibility, ensuring their work is accessible to a wide audience. Access options are fully open, allowing for seamless dissemination of knowledge in the ongoing battle against infectious diseases. With an established history of publishing groundbreaking studies, BMC Infectious Diseases plays a crucial role in addressing critical issues and advancing research in the ever-evolving landscape of infectious diseases.

Microbial Drug Resistance, published by MARY ANN LIEBERT, INC, is a pivotal journal that explores the critical intersection of microbiology and pharmacology with a keen focus on antibiotic resistance and related issues. Since its inception in 1995, this journal has established itself as a vital resource for researchers, healthcare professionals, and students, offering a platform for innovative studies that inform the global response to antimicrobial resistance. With a commendable position in the Category Quartiles, ranked Q2 in Medicine (miscellaneous) and Q2 in Pharmacology for 2023, it caters to a multidisciplinary audience by addressing the implications of microbial resistance within various medical contexts. Although currently non-Open Access, the journal allows subscribers and institutions to access high-quality, peer-reviewed research, directly impacting policy and practice in healthcare settings. Committed to advancing our understanding and combating the challenges posed by resistant microbes, Microbial Drug Resistance remains an essential publication in the fields of microbiology, immunology, and pharmacology.